Gregory Ciongoli
Vermögen: 14 Mio $ am 30.09.2026
Vermögen: 14 Mio $ am 30.09.2026
Mr. Gregory A. Ciongoli is an Independent Director at Gossamer Bio, Inc., an Independent Director at REGENXBIO, Inc., a Chairman at Atara Biotherapeutics, Inc. and a Managing Partner at Adiumentum Capital Management LLC.
He is on the Board of Directors at Gossamer Bio, Inc., REGENXBIO, Inc. and Zymeworks, Inc. Mr. Ciongoli was previously employed as a Partner by The Baupost Group LLC.
He received his undergraduate degree from Woodrow Wilson School of Public & International Affairs and an MBA from Harvard Business School.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
ZYMEWORKS INC. 0.7% | 12.01.2026 | 493’500 ( 0.7% ) | 13 Mio $ | 30.09.2026 |
REGENXBIO, INC. 0.18% | 27.08.2026 | 118’035 ( 0.18% ) | 888 804 $ | 30.09.2026 |
| 09.06.2026 | 12’000 ( 0.12% ) | 102 000 $ | 30.09.2026 | |
GOSSAMER BIO, INC. -.--% | 23.09.2026 | 0 ( -.--% ) | - $ | 30.09.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Vorsitzender | 03.09.2025 |
| ZYMEWORKS INC. | Direktor/Vorstandsmitglied | 11.08.2025 |
| REGENXBIO INC. | Direktor/Vorstandsmitglied | 25.08.2026 |
| GOSSAMER BIO, INC. | Direktor/Vorstandsmitglied | 16.09.2026 |
| Unternehmen | Position | Ende |
|---|---|---|
The Baupost Group LLC
The Baupost Group LLC Investment ManagersFinance Baupost is an opportunistic, value-oriented, open mandate investor that seeks to invest their capital to achieve attractive risk-adjusted returns over an extended period of time. The firm seeks to invest in assets which are undervalued relative to their market price. | Corporate Officer/Principal | - |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 7 |
|---|---|
The Baupost Group LLC
The Baupost Group LLC Investment ManagersFinance Baupost is an opportunistic, value-oriented, open mandate investor that seeks to invest their capital to achieve attractive risk-adjusted returns over an extended period of time. The firm seeks to invest in assets which are undervalued relative to their market price. | Finance |
REGENXBIO, Inc.
REGENXBIO, Inc. Pharmaceuticals: MajorHealth Technology Develops gene therapy | Health Technology |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases | Health Technology |
Woodrow Wilson School of Public & International Affairs
Woodrow Wilson School of Public & International Affairs Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Gossamer Bio, Inc.
Gossamer Bio, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing and commercializing therapeutics for immunology, inflammation and oncology diseases | Health Technology |
Zymeworks, Inc.
Zymeworks, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen